menu

Better Early Than Late: CDK4/6 Inhibition in HR +, HER2- Early Breast Cancer

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Better Early Than Late: CDK4/6 Inhibition in HR+, HER2- Early Breast Cancer

3 chapters
Play All
0.50 credits
30 minutes
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    HR+/HER2- breast cancer accounts for approximately 70% of early breast cancer. Now that the CDK4/6 inhibitor abemaciclib has been approved in the United States and internationally for the treatment of HR+/HER2- early breast cancer, it’s important to keep up with the latest data for its use. Listen in so Drs. Hope Rugo and Peter Schmid can keep you up to date on the most effective ways to treat your patients.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Hope Rugo, MD, FASCO
    Professor, Department of Medicine (Hematology/Oncology)
    Director, Breast Oncology and Clinical Trials Education
    UCSF Helen Diller Family Comprehensive Cancer Center
    San Francisco, CA

    Research: Astellas, AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech/Roche, Gilead Sciences, Merck, Novartis, OBI, Pfizer, Seattle Genetics, Sermonix
    Consultant or Advisory: AstraZeneca, Blueprint Medicines, Napo, Puma Biotechnology
    Travel support to academic meetings: AstraZeneca, Gilead, Merck

    Peter Schmid, FRCP, MD, PhD
    Chair of Cancer Medicine
    Barts Cancer Institute 
    Queen Mary University of London
    London, England 

    Research: Amgen Inc., Astellas, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Medivation Inc., a Pfizer Company, Novartis, OncoGenex Pharmaceuticals Inc., Roche Laboratories Inc.
    Consulting Fees: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc., Celgene Corporation, Eisai Inc., Gilead Sciences Inc., Lilly, Merck, Merck Sharp & Dohme LLC, Novartis, Pfizer Inc., Puma Biotechnology Inc., Roche Laboratories Inc., Seagen Inc.

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Jenn Brutsche has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Mara Siegel has nothing to disclose.
    • Rosanne Strauss has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    1. Evaluate the risk of recurrence in patients with HR+/HER2- early-stage breast cancer
    2. Assess the efficacy and safety of adjuvant CDK4/6 inhibitors in patients with HR+/HER2- early breast cancer
    3. Incorporate clinicopathologic assessments and patient-related factors to select adjuvant therapy for patients with HR+/HER2- early breast cancer
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists and pathologists around the world.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and  La Fundación ECO (ECO Foundation). GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .50 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

       

    AGILEAcademy for Global Interprofessional Learning and Education – designs, develops, and delivers education across a broad spectrum of diseases and clinical conditions. Our mission is to serve as a trusted source of clinical information that helps healthcare professionals improve competence, performance, and patient outcomes.

  • Commercial Support

    This activity is supported by an independent educational grant from Eli Lilly and Company.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and AGILE. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of AGILE you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

    Disclaimer: Some products discussed in this activity may not have received regulatory approval by the US FDA for the treatment of patients. The FDA has stated that “good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgement.”  

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    HR+/HER2- breast cancer accounts for approximately 70% of early breast cancer. Now that the CDK4/6 inhibitor abemaciclib has been approved in the United States and internationally for the treatment of HR+/HER2- early breast cancer, it’s important to keep up with the latest data for its use. Listen in so Drs. Hope Rugo and Peter Schmid can keep you up to date on the most effective ways to treat your patients.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Hope Rugo, MD, FASCO
    Professor, Department of Medicine (Hematology/Oncology)
    Director, Breast Oncology and Clinical Trials Education
    UCSF Helen Diller Family Comprehensive Cancer Center
    San Francisco, CA

    Research: Astellas, AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech/Roche, Gilead Sciences, Merck, Novartis, OBI, Pfizer, Seattle Genetics, Sermonix
    Consultant or Advisory: AstraZeneca, Blueprint Medicines, Napo, Puma Biotechnology
    Travel support to academic meetings: AstraZeneca, Gilead, Merck

    Peter Schmid, FRCP, MD, PhD
    Chair of Cancer Medicine
    Barts Cancer Institute 
    Queen Mary University of London
    London, England 

    Research: Amgen Inc., Astellas, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Medivation Inc., a Pfizer Company, Novartis, OncoGenex Pharmaceuticals Inc., Roche Laboratories Inc.
    Consulting Fees: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc., Celgene Corporation, Eisai Inc., Gilead Sciences Inc., Lilly, Merck, Merck Sharp & Dohme LLC, Novartis, Pfizer Inc., Puma Biotechnology Inc., Roche Laboratories Inc., Seagen Inc.

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Jenn Brutsche has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Mara Siegel has nothing to disclose.
    • Rosanne Strauss has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    1. Evaluate the risk of recurrence in patients with HR+/HER2- early-stage breast cancer
    2. Assess the efficacy and safety of adjuvant CDK4/6 inhibitors in patients with HR+/HER2- early breast cancer
    3. Incorporate clinicopathologic assessments and patient-related factors to select adjuvant therapy for patients with HR+/HER2- early breast cancer
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists and pathologists around the world.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and  La Fundación ECO (ECO Foundation). GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .50 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

       

    AGILEAcademy for Global Interprofessional Learning and Education – designs, develops, and delivers education across a broad spectrum of diseases and clinical conditions. Our mission is to serve as a trusted source of clinical information that helps healthcare professionals improve competence, performance, and patient outcomes.

  • Commercial Support

    This activity is supported by an independent educational grant from Eli Lilly and Company.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and AGILE. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of AGILE you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

    Disclaimer: Some products discussed in this activity may not have received regulatory approval by the US FDA for the treatment of patients. The FDA has stated that “good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgement.”  

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule29 Mar 2024